Posted on Sunday, 27th December 2009 by admin
Shares in biotechnology company Pharmaxis dropped 6 per cent this morning after the US Food and Drug Administration (FDA) knocked back a new drug application for its asthma diagnosis product, Aridol. In a letter sent to Pharmaxis by the FDA, the government regulator said it had observed deficiencies at three subcontracting manufacturing facilities. Pharmaxis chief [...]
Tags: Fda, Fda Rebuff
Comments (0)